LEO Pharma

LEO PHARMA LAUNCHES AD DAYS AROUND THE WORLD CAMPAIGN TO RAISE AWARENESS OF THE IMPACT OF ATOPIC DERMATITIS ACROSS CULTURES

Share
• In partnership with Global patient advocate Ashley Ann Lora, AD Days Around the World explores the impact of atopic dermatitis (AD) on the lives of individuals around the world living with this chronic and debilitating skin disease • The campaign features the emotional journey of four patient advocates from France, Italy, Germany and Spain and showcases the impact that AD has on people, regardless of culture or geography

BALLERUP, Denmark, 3 October 2022– LEO Pharma A/S, a global leader in medical dermatology, today launched AD Days Around the World, a global disease awareness campaign that highlights the experiences of people living with atopic dermatitis (AD) – the most common form of eczema.1 In collaboration with patient advocacy organizations in France, Italy, Germany and Spain, the campaign shares real patient stories to educate and inform people living with AD that regardless of nationality or culture, there is hope to triumph over adversity, despite common everyday challenges.

The campaign features Global patient advocate Ashley Ann Lora, who travels from the United States to France, Italy, Germany and Spain to meet with and document the emotionally compelling stories of four women – Marjolaine, Laura, Julia and África – who are living with AD, each at a different stage in their life. Through in-depth interviews, the documentary-style videos show audiences what it is like to live with and navigate the challenges associated with AD, and showcase how each of these resilient women has found peace, joy and empowerment over time. Their shared experiences and advice are as inspirational as they are informative.

“People don’t see eczema as a big deal, but it can cause so much suffering,” explained Ashley Ann Lora. “My hope is that the experiences shared through these stories will help people living with AD feel seen, heard and connected to others around the world with this condition. I also hope these personal stories help others gain a better understanding of their own eczema and their relationship with this condition. People living with AD don’t have to suffer; there are resources to help manage the condition and ways to enjoy life alongside it.”

“Atopic dermatitis is about more than just skin, and you never know where you might find your healing. For me, discovering dance and movement therapy transformed the way I see my eczema and today is a very important part of how I manage my condition,” said Marjolaine, a patient advocate living in France. “It is not one size fits all and different things will work for different people. I hope that my story will help others battling with atopic dermatitis to find what works for them.” 

The campaign offers access to these inspiring stories through www.ADDaysAroundTheWorld.com. Patients living with AD can watch the full video series featuring each patient advocate, learn more about AD, download a discussion guide to help facilitate better conversations with their healthcare professionals and access information about local patient advocacy organizations in each country.

“LEO Pharma is proud to have the opportunity to work with these inspiring patient advocates on AD Days Around the World. We know dermatology goes beyond the skin, and in our industry, we have the responsibility to see the whole patient when it comes to care,” said Christophe Bourdon Chief Executive Officer, LEO Pharma A/S.“Our hope is that through this campaign, and the inspiring stories of África, Laura, Julia and Marjolaine, other people living with AD realize there is life beyond an AD diagnosis and resources available to help them manage their skin condition.”

About atopic dermatitis

Atopic dermatitis is a chronic, inflammatory skin disease characterized by intense itch and eczematous lesions.2 Atopic dermatitis is the result of skin barrier dysfunction and immune dysregulation, leading to chronic inflammation.3

 

About Ashley Ann Lora

Global patient advocate and campaign host Ashley Ann Lora has been living with AD for more than 25 years. As a passionate global advocate, she uses the power of vulnerability to speak up for patients and advises on the needs of the AD community. Through her social platform, she is able to connect with others to share her journey of living with AD and provide hope and optimism for others.

- - - 

References

  1. National Eczema Association. What is atopic dermatitis? https://nationaleczema.org/eczema/types-of-eczema/atopic-dermatitis/ 
  2. Weidinger S, et al. Atopic dermatitis. Lancet. 2016;387(10023):1109–1122.
  3. Boguniewicz M, et al. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246.

Contacts

Contact:
David Patti
LEO Pharma, Global Product Communications
+1 973 796 7706
DAPAI@leo-pharma.com


Jes Broe Frederiksen
LEO Pharma, Global Product Communications
+45 53 60 59 48
JEBFE@leo-pharma.com

About LEO Pharma

LEO Pharma
LEO Pharma
Industriparken 55
2750 Ballerup

4494 5888http://www.leo-pharma.com/

About LEO Pharma

LEO Pharma is a global company dedicated to advancing the standard of care for the benefit of people with skin conditions, their families and society. Founded in 1908 and majority owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, and today, the company offers a wide range of therapies for all disease severities. LEO Pharma is headquartered in Denmark with a global team of 5,200 people, serving millions of patients across the world. In 2021, the company generated net sales of DKK 9,957 million.

Subscribe to releases from LEO Pharma

Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from LEO Pharma

LEO Pharma Receives Positive CHMP Opinion of Anzupgo® (delgocitinib cream) for the Treatment of Adults with Moderate to Severe Chronic Hand Eczema (CHE)26.7.2024 08:00:00 CEST | Pressemeddelelse

The positive opinion marks the latest step towards marketing authorization in the European Union (EU), with a final decision from the European Commission (EC) now pending. If approved, delgocitinib cream will be the first topical treatment specifically indicated for adults with moderate to severe CHE for whom topical corticosteroids are inadequate or inappropriate. The positive opinion is based on results from the DELTA phase 3 program, which includes the randomized, vehicle-controlled DELTA 1 and DELTA 2 clinical trials, (1,2,3) and the DELTA 3 open-label extension trial.(4)

LEO Pharma announces changes to its Global Leadership Team4.7.2024 14:10:00 CEST | Pressemeddelelse

LEO Pharma today announced that Nathalie Daste, Executive Vice President of Global People & Corporate Affairs, has decided to resign her position and leave LEO Pharma due to personal reasons. Christophe Bourdon, CEO of LEO Pharma, said: “I want to express heartfelt gratitude to Nathalie for her dedication to the journey we are currently on. In the Global Leadership Team, we will miss Nathalie, her engagement, and her fresh ideas, but I fully understand the need to put family first.” Nathalie Daste said: “It is with mixed emotions that I share the news of my departure from this remarkable organization. Due to unforeseen family circumstances, I have made the difficult decision to step away from my role. While it is hard to bid farewell to such a talented and dedicated team, I am confident that the organization will continue to thrive and achieve great things.” Effective immediately, Michael Meyer, currently Head of HR Business Partnering and an experienced HR leader, will step in until a

LEO Pharma announces topline results of phase 3 trial in China for Enstilar® (LEO 90100) demonstrating superiority in adult Chinese subjects with stable plaque psoriasis7.5.2024 20:00:00 CEST | Pressemeddelelse

Enstilar® (LEO 90100) showed superiority over Daivobet® ointment in primary and both secondary endpoints in the testing hierarchy showing improved efficacy in reducing the severity and extent of stable plaque psoriasis. Overall, both Daivobet ointment and Enstilar – each of them LEO Pharma products – were well tolerated. Safety profiles were consistent with previous trial findings and as expected with no new safety concerns identified. The trial is a commitment of LEO Pharma’s expanding presence in China, making a fundamental difference for Chinese patients living with psoriasis through additional treatment options. Enstilar – a unique cutaneous foam formulation built on the active ingredients of Daivobet – is a global market leader in topical psoriasis.

Solid start to the year: 13% revenue growth driven by strong performance in dermatology3.5.2024 09:00:00 CEST | Pressemeddelelse

Q1 2024 Trading Update (Unaudited): In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER). The dermatology portfolio saw accelerated growth in revenue of 16%. The acquisition of TMB-001 to the treatment of congenital ichthyosis added a late-stage asset to LEO Pharma’s medical dermatology pipeline, and delgocitinib for chronic hand eczema (CHE) is on track for its planned European launch in Q4 2024. Full-year outlook has been revised slightly upwards.

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye